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ABSTRACT
Over the past decade, through genome-wide association studies, more than 300 genetic variants have been identified to be associ-
ated with either BMD or fracture risk. These genetic variants are common in the general population, but they exert small to modest
effects on BMD, suggesting that the utility of any single variant is limited. However, a combination of effect sizes from multiple var-
iants in the form of the polygenic risk score (PRS) can provide a useful indicator of fracture risk beyond that obtained by conventional
clinical risk factors. In this perspective, we review the progress of genetics of osteoporosis and approaches for creating PRSs, their
uses, and caveats. Recent studies support the idea that the PRS, when integrated into existing fracture prediction models, can help
clinicians and patients alike to better assess the fracture risk for an individual, and raise the possibility of precision risk assessment. ©
2020 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
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Consider the following two 70-year-old women. Case 1 hasfemoral neck BMD of 0.72 g/cm2 (eg, nonosteoporosis),
has no prior fracture, but fell once over the past 12 months. Case
2 has femoral neck BMD of 0.65 g/cm2 (eg, osteoporosis), has no
prior fracture, and had no fall during the past 12 months. If the
two women have genotypes that are associated with an osteo-
porosis phenotype, how can the genetic data help inform their
fracture risk? Below, we review the genetic influence on osteopo-
rosis phenotypes and the generation, as well as the application
of the polygenic risk score (PRS) in individualized fracture risk
assessment.
The Genetics of Osteoporosis
The genetics of osteoporosis has, over the past five decades,
evolved through five paradigms: heritability study, candidate
gene study, genome-wide association study (GWAS), and
recently, the PRS and whole-genome sequencing. Twin studies
in the 1980s and 1990s showed that up to 80% of the variance
in BMD was attributable to genetic factors.(1,2) Twin studies also
showed that between 25% to 35% of the variance in the liability
to fracture is heritable,(3,4) consistent with the observation that
women with a familial history of hip fracture have a twofold
increase in the risk of hip fracture.(5) Moreover, genetic factors
account for a large proportion of variance in recognized risk
factors for fracture such as bone loss,(6) quantitative
ultrasound,(7) and bone turnover markers.(8) These lines of evi-
dence have established that heredity is an important risk factor
for osteoporosis and fracture risk.
Although the demonstration of hereditary effect on osteopo-
rosis risk is relatively easy, the identification of specific genes that
contribute to the risk has proven to be a formidable task. After a
series of candidate gene studies, a number of “osteoporosis
genes” (including, but not limited to, vitamin D receptor [VDR],
collagen type 1 alpha 1 genes) have been identified.(9) However,
these candidate gene studies were marred by conflicting find-
ings, limited reproducibility, and possibly false-positives,(10)
which were perhaps based mainly on the lack of statistical
power.(11)
Instead of focusing on a biologically plausible candidate gene,
a GWAS offers a hypothesis-free method of searching for puta-
tive genes in the entire genome without any assumptions about
the location and functional significance of loci or their prod-
ucts.(12) The thinking behind a GWAS is actually the “common
disease–common variant” hypothesis, which postulates that
the genetic component of common diseases (such as osteoporo-
sis) is made up of a large number of putative alleles that are com-
mon (>5%) in the general population.(13)
Although it is a hypothesis-free approach, a GWAS has been
successful in identifying multiple variants that are associated
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with BMD or fracture risk. A significant breakthrough was
reported in a seminal study that analyzed 301,019 variants in
~14,000 individuals of White background, and discovered 77 var-
iants that were associated with BMD at the genome-wide signif-
icance level.(14) Some of these variants are located close to or
within genes that are known to have important biologic roles
in bone metabolism, such as RANK, RANKL, osteoprotegerin
(OPG), estrogen receptor 1 (ESR1), and zinc finger and BTB
domain containing 40 (ZBTB40). Apart from those variants, the
study also identified several variants in and around the VDR
and low-density lipoprotein receptor-related protein 5 (LRP5)
genes that had been intensively examined in candidate gene
studies.
Another seminal study comprised of 81,949 cases and 102,444
controls, largely of White background, identified 56 loci that
were associated with BMD and 13 SNPs associated with frac-
ture.(15) Several of these loci or SNPs also cluster within or near
the RANK–RANKL–OPG system, mesenchymal stem cell differen-
tiation, endochondral ossification, and Wnt signaling pathways.
A more recent study using the resource of UK Biobank identified
518 loci associated with heel ultrasound measurements, of
which 301 were new loci.(16) The list of genetic variants identified
so far is unlikely the final list, as ongoing studies are likely to iden-
tify more variants that contribute to the susceptibility to osteo-
porosis and fracture.
The identified variants have two common characteristics:
They are carried by a large proportion of people, and they confer
modest effect sizes. Indeed, the frequency of the minor allele for
all variants discovered so far ranged mostly between 5% and
45% in the general population. Moreover, the strength of associ-
ation between these variants and traits is modest or verymodest.
Most of the variants that are associated with fracture risk had
modest odds ratios (ORs; ie, <1.2). For example, the 77 variants
in the first major GWAS accounted for only 3% of the total vari-
ance in hip and spinal BMD,(14) and the 518 variants in the UK
Biobank study accounted for 20% of the variance in heel ultra-
sound measurement. In terms of fracture association, virtually
all variants confer modestly increased odds of fracture by a few
percentage points, mostly closer to 5% and albeit some rare loci
up to 20%.
Themodest effect size of genetic variants implies that the pre-
dictive value of any single genetic variant is likely limited; this is
entirely expected by simple epidemiologic principle.(17) For
instance, for a genetic variant with OR between 1.1 and 1.2,
and assuming that the 5-year incidence of fracture is 10%, the
area under the ROC curve (AUC) associated with this genetic var-
iant is expected to be 0.52 to 0.55. Thus, any single variant of and
by itself is unlikely to be useful for prediction.
On the other hand, a combination of multiple genetic vari-
ants, even with modest effect sizes, could be useful. Theoreti-
cally, it can be shown that for a given number of variants, the
discriminatory power (eg, AUC) increases proportionally to the
effect sizes.(18) For example, for a combination of 50 genetic
variants, each with an OR = 1.1, the AUC value is expected to
be 0.63; however, if each variant has an OR = 1.2, the AUC is
expected to be 0.73. From this simulation, it can also be inferred
that a model with 500 variants, each with OR = 1.1, can yield an
AUC >0.80 (Table 1). The idea of combining multiple variants
gives rise to a construct known as the polygenic risk score,
which is poised to improve patient outcomes via precision
medicine,(19) but raises concerns of health disparity between
ethnicities.(20)
The Polygenic Risk Score
The PRS can be defined as a quantitative index of the genetic
burden related to a specific disorder and is specific to an individ-
ual. Operationally, there are several ways to create a PRS. The
simplest approach is to assign a risk value of 0 if an individual
is a noncarrier of a risk allele, 0.5 or 1 if a carrier, and 1 or 2 if
homozygous for that allele, and then sum the score across vari-
ants for the individual. This simple approach implicitly assumes
that all variants contribute equally to the trait variation, which
is unlikely true in most real-world situations. Therefore, a better
approach is to sum the trait-associated alleles weighted by their
effect sizes. The trait-associated or risk allele is defined as an
allele that is more common in cases than controls. The effect size
can be a regression coefficient (for quantitative trait) or log OR
(for categorical traits). In either approach, because the PRS is
aggregated from multiple variants and effect sizes, it is likely to
be unique to an individual. Moreover, given its aggregation
nature, the PRS can be seen as an index of an individual’s genetic
liability to develop a disorder.
Statistically, the PRS tends to show a normal or approximately
normal distribution in the general population. The difference in
the PRS between those with and without a disorder is mainly
governed by the mean, not the variance of the distribution.
The number of variants can range between a few and millions
that are identified across loci from GWASs. Intuitively, only vari-
ants that are statistically robust at genome-wide significance
level should be included in the derivation of the PRS because var-
iants that do not reach the significance level are unlikely to con-
tribute to the variation in the trait of interest. However, in reality,
some PRSs were constructed from many variants (eg, hundreds
of thousands of variants) across the genome, even though they
show very weak association with a trait. This practice of including
a large number of variants is based on the view that many gen-
uine associations are potentially missed because of inadequate
power in the original GWAS.
Another approach to construct the PRS is to use knowledge of
biological pathways or processes to select relevant variants. For
example, one can select all variants that are involved with
protein–protein interactions or involvement in signaling path-
ways. However, it remains to be shown whether pathway-based
PRSs can predict phenotypic variation more robustly than the
“traditional” PRS, which is based on the totality of disease risk.
What Can the Polygenic Risk Score Be Used For?
An obvious application of a PRS in clinical osteoporosis care is
fracture risk assessment. At present, the assessment of fracture
risk for an individual is primarily done using tools such as the Gar-
van fracture risk calculator,(21) the fracture risk assessment tool
(FRAX),(22) and QFract software.(23) Although these tools have
proven useful for identifying high-risk individuals, their predic-
tive performance is a matter for improvement. In external valida-
tion studies, the AUC of the Garvan and FRAX models ranged
between 0.61 and 0.85, with average being ~0.70,(24–27) amodest
discrimination. Ideally, to be useful, predictive capacity would
need to be high predictive (AUC ~0.80). Furthermore, FRAX tends
to underestimate the risk of fracture by as much as 50%,(24) in
part because factors that are associated with higher risk are also
associated with earlier mortality for which the estimated risk was
discounted. Thus, there is room for further improvement in
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fracture prediction, and genetic factors have emerged as an
important for fracture risk prediction.
Although none of the existing fracture prediction tools incor-
porates genetic data, recent studies have suggested that the PRS
can be a useful addition. We have created a PRS called osteoge-
nomic profile,(28) which is based on 62 variants that are associ-
ated with BMD.(14) We found that each unit increase in the PRS
was associated with a hazard ratio of 1.20 (95% CI, 1.04–1.38)
for fracture, independent of age, prior fracture, and falls.(28)
Importantly, when the PRS was included in the existing Garvan
fracture risk calculator model,(29) the reclassification of fracture
versus nonfracture was significantly improved.(28) In the MrOS
(Osteoporotic Fractures in Men study) cohort, a PRS constructed
from 63 genetic BMD-associated variants was also associated
with the risk of total fracture.(30) In postmenopausal women of
Korean background, a PRS constructed from 39 variants
improved the precision of nonertebral fracture prediction in
the general population,(31) as well as in patients on bisphospho-
nate.(31,32) QUS is associated with fracture,(33) and the PRS gener-
ated fromQUS can also help identify individuals at risk of fracture
or osteoporosis.(34,35) Taken together, a PRS constructed from
BMD-associated variants could be used as a genetic factor for
fracture prediction.
The PRS can also be used for assessing bone loss in an individ-
ual. Bone loss is highly variable between individuals, not simply
because of measurement error, but also because of genetic fac-
tors.(6) Although specific genes for bone loss have not been iden-
tified, a PRS has been shown to be associated with bone loss in
postmenopausal women.(36) In a longitudinal study in which
BMD of 860 postmenopausal women had been monitored for
up to 20 years, each unit higher PRS was associated with a
0.21% (standard error, 0.10) higher annual rate of bone loss at
the femoral neck. Of note, this association was independent of
baseline BMD and age. Moreover, each unit increase of PRS
was associated with 41% odds (95% CI, 1.07–1.87) of rapid bone
loss (defined as loss >1.2%/year). Thus, the PRS could be used as
an additional means for predicting bone loss in an individual.(36)
The PRS can be considered an index of family history. It is well-
known that a family history of fracture, especially a family history
of hip fracture, is a risk factor for fracture: Daughters of mothers
with a history of hip fracture have lower BMD than those whose
mothers did not have a hip fracture.(37) Women with a familial
history of hip fracture have a twofold increase in the risk of hip
fracture.(5) However, family history is an unreliable measure,
partly because of recall bias and in part because it relies on older
family members surviving to ages that mean they can contribute
useful information for risk. Thus, despite its potential, family his-
tory poorly captures the polygenic nature of risk. By contrast, the
PRS represents an individual’s overall genomic burden that is
heritable, making the PRS an attractive quantitative index of fam-
ily history.
What the Polygenic Risk Score Is Not
The PRS is not a diagnostic test. Like other risk assessment tools,
the PRS can only indicate the risk of fracture, but cannot categor-
ically establish whether an individual will or will not have a frac-
ture. However, the advantage of risk assessment via the PRS is
that it allows a life-time prediction well before the onset of frac-
ture. Although there is no “genetic therapy” for individuals at
high risk of fracture, this salient lifetime prediction may raise
immediacy of primary and secondary prevention behaviors in
those at heightened genetic risk.
The PRS alone is not informative of fracture status. That is, it
cannot reliably discriminate between those who will from those
who will not have a fracture. The PRSmust and should be used in
conjunction with established risk factors (eg, BMD, fall, personal
history of fracture) for assessing fracture risk. Still, the PRS could
be useful for the stratification of individuals in the general popu-
lation, which can be useful for public health intervention.
Caveats
Any scientifically useful measure should satisfy two basic criteria:
content validity and criterion validity. Content validity refers to
the extent to which the measure is representative of the entire
domain or content the measure seeks to reflect. Criterion validity
is the correlation between the new measure and an established
method (eg, the gold standard). Any use or interpretation of the
PRS must be considered in the context of these two types of
validity.
In the PRS context, genetic liability is the domain. The PRS,
which is constructed from a selected set of genetic variants,
could not capture the totality of genetic liability. As mentioned
above, different PRSs have been constructed using different
approaches and criteria. The selection of variants has largely
been based on P-value thresholds, so it is unlikely that they cap-
ture the totality of genetic liability. Logically, themore variants to
be included in the PRS (usually by relaxing P-value criteria) the
better content validity it is, and this has been shown in simula-
tion as well as empirical studies.(38) Moreover, rare variants (ie,
allelic frequencies <1%) that are not currently identified by
GWASs may account for a significant proportion of variance in
BMD,(39) but they are not included in the derivation of the PRS.
At present, most PRSs account for a small proportion of genetic
variance of BMD or fracture risk, and their content validity is an
open question.
Table 1. Utility of Genetic Profiling in Terms of AUC and Percentage of Net Reclassification Improvement
Number of variants
AUC
OR = 1.10 OR = 1.15 OR = 1.20 OR = 1.25 OR = 1.30
10 0.557 0.586 0.611 0.635 0.659
50 0.630 0.682 0.733 0.769 0.805
100 0.682 0.743 0.794 0.841 0.870
500 0.830 0.898 0.936 0.953 0.967
1000 0.895 0.943 0.966 0.977 0.983
Notes. Results were obtained by simulation with the following parameters: gene frequency = 0.5, risk threshold = 0.2, and 5-year incidence of frac-
ture = 0.1. AUC = Area under the receiver operating characteristic curve; OR = odds ratio.
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The criterion validity of the PRS also requires more consider-
ation. BMD has been the gold standard for assessing fracture risk,
and BMD has been shown to be valid in terms of measured con-
tent and its biology criterion. In the PRS context, the correlation
between a PRS and BMD is low, with most correlation coeffi-
cients being <0.20, suggesting that PRSs have a low level of cri-
terion validity.
The PRS is, as expected from the operational definition, sensi-
tive to allele frequency and effect size of variants. Allele fre-
quency is known to be different between ethnicities, such that
an allele may be common in one ethnicity, yet may be rare in
another ethnicity. Furthermore, the effect size associated with
an allele can be different between ethnicities because of interac-
tion with environmental factors. Furthermore, population history
(eg, effective population size, immigration, and inbreeding) and
inheritance patterns may be different between ethnic groups.
Thus, a PRS constructed from an ethnicity may not be applicable
to another ethnicity. At present, most PRSs in the field of osteo-
porosis were derived from White populations, and these PRSs
may not be applicable to non-White populations.
It is now increasingly recognized that many chronic diseases
are biologically linked such that they form a network.(40) The dis-
eases within a network may share common sets of genetic vari-
ants. For instance, osteoporosis and obesity are known to be
linked, and eight genetic variants at the TBX15 gene were asso-
ciated with both body mass and estimated BMD.(41) It has been
suggested that genes associated with morphological pheno-
types, such as bone structure, evolve more slowly than those
associated with physiological phenotypes, such as bone turn-
over markers.(42) The implication of these complex relationships
is that the regression weight associated with a variant may be
different across diseases and environmental factors, but this pos-
sibility is not captured by a phenotype-specific PRS.
Another caveat of the PRS is its assumption of additive effects.
Because the PRS is the sum of weighted effect alleles, it implicitly
assumes that the effects of all variants are additive. However,
there is no logical reason to suggest that the effects are indepen-
dent; it is highly likely that the effect of one variant is dependent
on the other’s effect (ie, epistatic effects or gene–gene interac-
tion), and this would introduce bias into the risk estimates. How-
ever, current methodology and sample size do not allow a
complete dissection of higher-order gene–gene interactions
between genes. Nevertheless, in the presence of gene–gene
interactions, the simple additive PRS can be biased.
Another concern with the PRS is its cost effectiveness.
Although there have been no studies of the economic cost of
PRS in osteoporosis, studies in the field of cancer(43) and cardio-
vascular disease(44) suggest that the PRS is cost effective in the
prevention or improved management of disease. At present, it
is quite feasible to generate the PRS with hundreds of thousands
or even millions of SNPs for less than $100. Thus, in the long run,
the implementation of the PRS into clinical practice will be tech-
nically and economically feasible.
Back to the two cases, what can the PRS contribute to the pre-
diction of their fracture risk. The Garvan fracture risk calculator
predicts that the two women have the same 10-year risk of frac-
ture (24%), which may not be indicated for treatment. However,
if both women have a PRS in the top 5% percentile, then their
10-year risk of fracture is now 32%, which may be indicated for
treatment. Thus, knowing their genetic information in the form
of a PRS can potentially change the indication of treatment.
In summary, the PRS has emerged as a useful measure of
genetic propensity to a trait at the individual level that has
multiple applications. In the field of osteoporosis, the PRS could
be used for individualized fracture risk assessment in conjunc-
tion with existing prediction tools, prediction of bone loss, and
as a quantitative index of family history. The PRS could also be
used for risk stratification in the general population. However,
the application of the PRS has to be considered in the context
of its potential limitations concerning content and criterion
validity and underlying assumption of additive effects. In the
era of post-GWAS, when health care will be strongly influenced
by genomics and big data, the PRS, as a proxymeasure of genetic
liability, will likely have a place in clinical decision and precision
medicine.
Acknowledgments
This work is supported in part by a grant from the Amgen Com-
petitive Grant Program (2019) and NHMRC grant APP1195305.
Authorsʼ roles: Conceptualization: TVN, JAE; data curation and
simulation: TVN; writing original draft: TVN; reviewing and
approval of final version: TVN and JAE.
Peer Review
The peer review history for this article is available at https://
publons.com/publon/10.1002/jbm4.10411.
References
1. Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN, Eberl S.
Genetic determinants of bone mass in adults. A twin study. J Clin
Invest. 1987;80(3):706–10.
2. Nguyen TV, Howard GM, Kelly PJ, Eisman JA. Bone mass, lean mass,
and fat mass: same genes or same environments? Am J Epidemiol.
1998;147(1):3–16.
3. Deng HW, Chen WM, Recker S, et al. Genetic determination of Colles’
fracture and differential bone mass in women with and without Col-
les’ fracture. J Bone Miner Res. 2000;15(7):1243–52.
4. Michaelsson K, Melhus H, Ferm H, Ahlbom A, Pedersen NL. Genetic
liability to fractures in the elderly. Arch Intern Med. 2005;165(16):
1825–30.
5. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip frac-
ture in white women. Study of Osteoporotic Fractures Research
Group. N Engl J Med. 1995;332(12):767–73.
6. Makovey J, Nguyen TV, Naganathan V, Wark JD, Sambrook PN.
Genetic effects on bone loss in peri- and postmenopausal women:
a longitudinal twin study. J Bone Miner Res. 2007;22(11):1773–80.
7. Howard GM, Nguyen TV, Harris M, Kelly PJ, Eisman JA. Genetic and
environmental contributions to the association between quantita-
tive ultrasound and bone mineral density measurements: a twin
study. J Bone Miner Res. 1998;13(8):1318–27.
8. Tokita A, Kelly PJ, Nguyen TV, et al. Genetic influences on type I colla-
gen synthesis and degradation: further evidence for genetic regula-
tion of bone turnover. J Clin Endocrinol Metab. 1994;78(6):1461–6.
9. Ralston SH, de Crombrugghe B. Genetic regulation of bone mass and
susceptibility to osteoporosis. Genes Dev. 2006;20(18):2492–506.
10. Nguyen TV. Pharmacogenetics of anti-resorptive therapy efficacy: a
Bayesian interpretation. Osteoporos Int. 2005;16(8):857–60.
11. Huang QY, Recker RR, Deng HW. Searching for osteoporosis genes in
the post-genome era: progress and challenges. Osteoporos Int. 2003;
14(9):701–15.
12. WangWY, Barratt BJ, Clayton DG, Todd JA. Genome-wide association
studies: theoretical and practical concerns. Nat Rev Genet. 2005;6(2):
109–18.
13. Reich DE, Lander ES. On the allelic spectrum of human disease.
Trends Genet. 2001;17(9):502–10.
JBMR Plus (WOA)n 4 of 5 NGUYEN AND EISMAN
14. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, et al. Multiple
genetic loci for bone mineral density and fractures. N Engl J Med.
2008;358(22):2355–65.
15. Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide meta-
analysis identifies 56 bone mineral density loci and reveals 14 loci
associated with risk of fracture. Nat Genet. 2012;44(5):491–501.
16. Morris JA, Kemp JP, Youlten SE, et al. An atlas of genetic influences on
osteoporosis in humans and mice. Nat Genet. 2019;51(2):258–66.
17. Holtzman NA, Marteau TM. Will genetics revolutionize medicine? N
Engl J Med. 2000;343(2):141–4.
18. PepeMS, Gu JW, Morris DE. The potential of genes and other markers
to inform about risk. Cancer Epidemiol Biomarkers Prev. 2010;19(3):
655–65.
19. Sugrue LP, Desikan RS. What are polygenic scores and why are they
important? JAMA. 2019;321(18):1820–1.
20. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical
use of current polygenic risk scores may exacerbate health dispar-
ities. Nat Genet. 2019;51(4):584–91.
21. Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV. Development
of a nomogram for individualizing hip fracture risk in men and
women. Osteoporos Int. 2007;18(8):1109–17.
22. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the
assessment of fracture probability in men and women from the UK.
Osteoporos Int. 2008;19(4):385–97.
23. Hippisley-Cox J, Coupland C. Derivation and validation of updated
QFracture algorithm to predict risk of osteoporotic fracture in pri-
mary care in the United Kingdom: prospective open cohort study.
BMJ. 2012;344:e3427.
24. Bolland MJ, Siu AT, Mason BH, et al. Evaluation of the FRAX and Gar-
van fracture risk calculators in older women. J Bone Miner Res. 2011;
26(2):420–7.
25. Pluskiewicz W, Adamczyk P, Franek E, et al. Ten-year probability of
osteoporotic fracture in 2012 Polish women assessed by FRAX and
nomogram by Nguyen et al.-conformity between methods and their
clinical utility. Bone. 2010;46(6):1661–7.
26. Pluskiewicza W, Adamczykb P, Franekc E, et al. Conformity
between 10-year probability of any osteoporotic fracture assessed
by FRAX and nomogram by Nguyen et al. Bone. 2009;44(Suppl 2):
S229–S30.
27. Sandhu SK, Nguyen ND, Center JR, Pocock NA, Eisman JA, Nguyen TV.
Prognosis of fracture: evaluation of predictive accuracy of the FRAX
algorithm and Garvan nomogram. Osteoporos Int. 2010 May;21(5):
863–71.
28. Ho-Le TP, Center JR, Eisman JA, Nguyen HT, Nguyen TV. Prediction of
bone mineral density and fragility fracture by genetic profiling.
J Bone Miner Res. 2017;32(2):285–93.
29. Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV. Development
of prognostic nomograms for individualizing 5-year and 10-year frac-
ture risks. Osteoporos Int. 2008;19(10):1431–44.
30. Eriksson J, Evans DS, Nielson CM, et al. Limited clinical utility of a
genetic risk score for the prediction of fracture risk in elderly subjects.
J Bone Miner Res. 2015;30(1):184–94.
31. Lee SH, Lee SW, Ahn SH, et al. Multiple gene polymorphisms can
improve prediction of nonvertebral fracture in postmenopausal
women. J Bone Miner Res. 2013;28(10):2156–64.
32. Lee SH, Cho EH, Ahn SH, et al. Prediction of future osteoporotic frac-
ture occurrence by genetic profiling: a 6-year follow-up observa-
tional study. J Clin Endocrinol Metab. 2016 Mar;101(3):1215–24.
33. Moayyeri A, Adams JE, Adler RA, et al. Quantitative ultrasound of the
heel and fracture risk assessment: an updated meta-analysis. Osteo-
poros Int. 2012;23(1):143–53.
34. Kim SK. Identification of 613 new loci associated with heel bone min-
eral density and a polygenic risk score for bonemineral density, oste-
oporosis and fracture. PLoS One. 2018;13(7):e0200785.
35. Manousaki D, Forgetta V, Keller-Baruch J, et al. A polygenic risk score
as a risk factor for medication-associated fractures. J Bone Miner Res.
2020 Jun 8. https://doi.org/10.1002/jbmr.4104. Online ahead of print.
36. Ho-Le TP, Pham HM, Center JR, Eisman JA, Nguyen HT, Nguyen TV.
Prediction of changes in bone mineral density in the elderly: contri-
bution of "osteogenomic profile". Arch Osteoporos. 2018;13(1):68.
37. Seeman E. Reduced bone density in women with fractures: contribu-
tion of low peak bone density and rapid bone loss. Osteoporos Int.
1994;4(Suppl 1):15–25.
38. Chatterjee N, Wheeler B, Sampson J, Hartge P, Chanock SJ, Park JH.
Projecting the performance of risk prediction based on polygenic
analyses of genome-wide association studies. Nat Genet. 2013;45
(4):400–5 5e1-3.
39. Gibson G. Rare and common variants: twenty arguments. Nat Rev
Genet. 2012;13(2):135–45.
40. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL. The human
disease network. Proc Natl Acad Sci U S A. 2007;104(21):8685–90.
41. Zhou Y, Wu K, Shen H, Zhang J, Deng HW, Zhao LJ. Geographical dif-
ferences in osteoporosis, obesity, and sarcopenia related traits in
white American cohorts. Sci Rep. 2019;9(1):12311.
42. Park S, Yang JS, Kim J, et al. Evolutionary history of human disease
genes reveals phenotypic connections and comorbidity among
genetic diseases. Sci Rep. 2012;2:757.
43. Callender T, Emberton M, Morris S, et al. Polygenic risk-tailored
screening for prostate cancer: a benefit-harm and cost-effectiveness
modelling study. PLoS Med. 2019;16(12):e1002998.
44. Hynninen Y, LinnaM, Vilkkumaa E. Value of genetic testing in the pre-
vention of coronary heart disease events. PLoS One. 2019;14(1):
e0210010.
JBMR® Plus POLYGENIC RISK SCORE IN OSTEOPOROSIS 5 of 5 n
